Full Press Release Details
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that its Butterfly iQ+/iQ3 and Compass AI™ ultrasound solution have achieved GovRAMP and TX-RAMP Authorizations. The certifications authorize the Company to sell cloud services to all state and local government agencies, including in the state of Texas.
GovRAMP (formerly StateRAMP), a nationally recognized risk authorization management program, provides a standardized approach to assessing cloud products. Achieving GovRAMP Authorization demonstrates Butterfly's dedication to meeting the highest security and compliance standards, ensuring the trust and confidence of government agencies and organizations. In addition, the company has secured TX-RAMP Certification for the state of Texas, which is the only domestic state requiring a standalone authorization.
Butterfly’s probes paired with Compass AI™ cloud-based workflow software together offer a holistic, compliant, enterprise-ready point-of-care ultrasound solution. The solution has undergone a third-party assessment by the Audit firm A-LIGN and a quality review by the GovRAMP Program Management Office.
Butterfly’s Vice President, Enterprise Information Systems and Chief Information Security Officer, Mike Tieymeyer, shared, "Building on the momentum of multiple global accreditations accomplished in late 2025, we’re thrilled to further strengthen our security posture domestically. These latest achievements demonstrate our readiness to continue democratizing healthcare with versatile cloud-based ultrasound solutions that can safely, securely advance care delivery in state and local agencies.”
Government agencies and organizations can now confidently rely on Butterfly's GovRAMP and TX-RAMP Authorized solution to streamline their operations, reduce risk, and safeguard their data with enhanced security.
The news follows Butterfly’sOctober 2025 announcementregarding ISO 27001, SOC-2 Type 2, C5 Germany, and NHS DSPT global accreditations. Butterfly is expected to secure FedRAMP certification in 2026, and is pursuing HITRUST CSF r2, a NIST 800-53 (Rev-5) framework that unifies standards like HIPAA and GDPR.
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit:https://www.butterflynetwork.com/choose-your-country.